(Q33375650)

English

A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

author name string

M J Mackenzie

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

D Saltman

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

H Hirte

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Low

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C Johnson

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

G Pond

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M J Moore

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

22 June 2007

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

553-558

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s10637-007-9066-3

0 references

Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17585372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/17585372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/17585372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2004

1 reference

https://pubmed.ncbi.nlm.nih.gov/17585372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17585372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/17585372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/17585372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17585372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/17585372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17585372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17585372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17585372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17585372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule

1 reference

https://pubmed.ncbi.nlm.nih.gov/17585372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17585372

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-007-9066-3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33375650&oldid=1973248054"